Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clementia Pharmaceuticals, Inc.

http://clementiapharma.com/

Latest From Clementia Pharmaceuticals, Inc.

Ipsen Positive On Palovarotene Despite Troubled Past

Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.

Rare Diseases Drug Review

Sanofi Vaccines Chief Loew To Be Ipsen CEO

Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.

Leadership Strategy

New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.

Orthopedics Clinical Trials

Ipsen Upbeat Despite Palovarotene Pain

The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.

Sales & Earnings Rare Diseases
See All

Company Information

UsernamePublicRestriction

Register